Copyright Reports & Markets. All rights reserved.

Global Alpha Glucosidase Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Alpha Glucosidase Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Alpha Glucosidase Inhibitors Market Size Growth Rate by Product
      • 1.4.2 Dumping Syndrome
      • 1.4.3 Type 2 Diabetes
    • 1.5 Market by End User
      • 1.5.1 Global Alpha Glucosidase Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Online Pharmacies
      • 1.5.3 Retail Pharmacies
      • 1.5.4 Hospital Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Alpha Glucosidase Inhibitors Market Size
      • 2.1.1 Global Alpha Glucosidase Inhibitors Revenue 2014-2025
      • 2.1.2 Global Alpha Glucosidase Inhibitors Sales 2014-2025
    • 2.2 Alpha Glucosidase Inhibitors Growth Rate by Regions
      • 2.2.1 Global Alpha Glucosidase Inhibitors Sales by Regions
      • 2.2.2 Global Alpha Glucosidase Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Alpha Glucosidase Inhibitors Sales by Manufacturers
      • 3.1.1 Alpha Glucosidase Inhibitors Sales by Manufacturers
      • 3.1.2 Alpha Glucosidase Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Alpha Glucosidase Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Alpha Glucosidase Inhibitors Revenue by Manufacturers
      • 3.2.1 Alpha Glucosidase Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Alpha Glucosidase Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Alpha Glucosidase Inhibitors Price by Manufacturers
    • 3.4 Alpha Glucosidase Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Alpha Glucosidase Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Alpha Glucosidase Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Alpha Glucosidase Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Alpha Glucosidase Inhibitors Sales by Product
    • 4.2 Global Alpha Glucosidase Inhibitors Revenue by Product
    • 4.3 Alpha Glucosidase Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Alpha Glucosidase Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Alpha Glucosidase Inhibitors by Countries
      • 6.1.1 North America Alpha Glucosidase Inhibitors Sales by Countries
      • 6.1.2 North America Alpha Glucosidase Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Alpha Glucosidase Inhibitors by Product
    • 6.3 North America Alpha Glucosidase Inhibitors by End User

    7 Europe

    • 7.1 Europe Alpha Glucosidase Inhibitors by Countries
      • 7.1.1 Europe Alpha Glucosidase Inhibitors Sales by Countries
      • 7.1.2 Europe Alpha Glucosidase Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Alpha Glucosidase Inhibitors by Product
    • 7.3 Europe Alpha Glucosidase Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Alpha Glucosidase Inhibitors by Countries
      • 8.1.1 Asia Pacific Alpha Glucosidase Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Alpha Glucosidase Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Alpha Glucosidase Inhibitors by Product
    • 8.3 Asia Pacific Alpha Glucosidase Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Alpha Glucosidase Inhibitors by Countries
      • 9.1.1 Central & South America Alpha Glucosidase Inhibitors Sales by Countries
      • 9.1.2 Central & South America Alpha Glucosidase Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Alpha Glucosidase Inhibitors by Product
    • 9.3 Central & South America Alpha Glucosidase Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Alpha Glucosidase Inhibitors by Countries
      • 10.1.1 Middle East and Africa Alpha Glucosidase Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Alpha Glucosidase Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Alpha Glucosidase Inhibitors by Product
    • 10.3 Middle East and Africa Alpha Glucosidase Inhibitors by End User

    11 Company Profiles

    • 11.1 Pfizer
      • 11.1.1 Pfizer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Pfizer Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Pfizer Alpha Glucosidase Inhibitors Products Offered
      • 11.1.5 Pfizer Recent Development
    • 11.2 Bayer pharma
      • 11.2.1 Bayer pharma Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer pharma Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer pharma Alpha Glucosidase Inhibitors Products Offered
      • 11.2.5 Bayer pharma Recent Development
    • 11.3 Takeda
      • 11.3.1 Takeda Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Takeda Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Takeda Alpha Glucosidase Inhibitors Products Offered
      • 11.3.5 Takeda Recent Development
    • 11.4 Sun pharma
      • 11.4.1 Sun pharma Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sun pharma Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sun pharma Alpha Glucosidase Inhibitors Products Offered
      • 11.4.5 Sun pharma Recent Development
    • 11.5 Glenmark pharma
      • 11.5.1 Glenmark pharma Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Glenmark pharma Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Glenmark pharma Alpha Glucosidase Inhibitors Products Offered
      • 11.5.5 Glenmark pharma Recent Development
    • 11.6 Torrent
      • 11.6.1 Torrent Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Torrent Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Torrent Alpha Glucosidase Inhibitors Products Offered
      • 11.6.5 Torrent Recent Development
    • 11.7 Hexalag
      • 11.7.1 Hexalag Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Hexalag Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Hexalag Alpha Glucosidase Inhibitors Products Offered
      • 11.7.5 Hexalag Recent Development
    • 11.8 Unichem
      • 11.8.1 Unichem Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Unichem Alpha Glucosidase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Unichem Alpha Glucosidase Inhibitors Products Offered
      • 11.8.5 Unichem Recent Development

    12 Future Forecast

    • 12.1 Alpha Glucosidase Inhibitors Market Forecast by Regions
      • 12.1.1 Global Alpha Glucosidase Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Alpha Glucosidase Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Alpha Glucosidase Inhibitors Market Forecast by Product
      • 12.2.1 Global Alpha Glucosidase Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Alpha Glucosidase Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Alpha Glucosidase Inhibitors Market Forecast by End User
    • 12.4 North America Alpha Glucosidase Inhibitors Forecast
    • 12.5 Europe Alpha Glucosidase Inhibitors Forecast
    • 12.6 Asia Pacific Alpha Glucosidase Inhibitors Forecast
    • 12.7 Central & South America Alpha Glucosidase Inhibitors Forecast
    • 12.8 Middle East and Africa Alpha Glucosidase Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Alpha Glucosidase Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day.
      Acarbose is the most widely prescribed of the three currently available (Acarbose, Miglitol, and Voglibose) alpha‐glucosidase inhibitors and has been used in the management of hyperglycemia for years.
      The global Alpha Glucosidase Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alpha Glucosidase Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Alpha Glucosidase Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alpha Glucosidase Inhibitors in these regions.
      This research report categorizes the global Alpha Glucosidase Inhibitors market by top players/brands, region, type and end user. This report also studies the global Alpha Glucosidase Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Pfizer
      Bayer pharma
      Takeda
      Sun pharma
      Glenmark pharma
      Torrent
      Hexalag
      Unichem

      Market size by Product
      Dumping Syndrome
      Type 2 Diabetes
      Market size by End User
      Online Pharmacies
      Retail Pharmacies
      Hospital Pharmacies

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Alpha Glucosidase Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Alpha Glucosidase Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Alpha Glucosidase Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Alpha Glucosidase Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Alpha Glucosidase Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (g). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alpha Glucosidase Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now